|
Published by: Datamonitor
Published: Aug. 14, 2001 - 172 Pages
Table of Contents
DATAMONITOR HEALTHCARE
CONTACT DETAILS
Scope
Key Metrics
DEFINITION AND EPIDEMIOLOGY
Disease Definitions
Vasomotor symptoms
Urogenital atrophy
Osteoporosis
Cardiovascular Conditions
Epidemiology
Menopause
Osteoporosis
TREATMENT PATTERNS
Screening
Diagnosis
Prophylaxis
Treatment rates and segmentation
Treatment practices for osteoporosis and menopausal disorders
Treatment options
Treatment algorithms
Preferred products by region
Use of HRT
Factors affecting treatment decisions
Future drivers of treatment
MARKET DYNAMICS
Key Companies
Global players
Company portfolios
Key marketed products
Class analysis
Analysis of leading products
Analysis of leading products
Regional analysis
Environmental factors
COMPANY STRATEGIES
Reformulation of an existing product
Case Study: Merck & Co's Reformulation of Fosamax
Addition of a novel drug delivery mechanism
Case study: Launch of Galen's Menoring
Promotion of combination therapy
Easing the transition from oral contraceptives to HRT
Driving the osteoporosis prevention market
Developing more natural products to fulfill a growing demand
Case study: The addition of Totelle to Wyeth's HRT portfolio
Development of low dose HRT formulations
Conducting additional clinical trials
Case Study: Eli Lilly's development of Evista
Pursuing niche indications
Capitalizing on the growing size of the Women's Health market
PIPELINE ANALYSIS
Unmet needs
Pipeline analysis
Hormone-based therapies
HRT
SERMs
Bisphosphonates
Other classes
FORECASTS 2001-2008
Epidemiology forecasts
Menopause
Osteoporosis
Total Market
Sales Forecasts
Key Factors Impacting the Forecast
Market Forecasts by Drug Class
Sales forecasts
Key Factors Influencing the Drug Class Forecasts
Forecasts for Leading Products
Sales Forecasts
Key Factors Impacting the Forecasts
APPENDIX
Table of tables
Table of figures
Bibliography
Epidemiology
Clinical trial data
Treatment information
Sales data research methodology
Introduction
Hypothesis formulation
Hypothesis testing
Data verification with key contacts
Quality control
Quantification of data reliability
Confidence ratings
Exchange rates
R&D research methodology
Introduction
Hypothesis formulation
Hypothesis testing
Data verification and quality control
AbstractCurrently, only a low number of patients are presenting for or being referred for osteoporosis testing. However, there are several opportunities available for manufacturers of HRT, SERMs and bisphosphonate to drive sales of their products for the primary indication of osteoporosis prevention. A variety of possible strategies will help achieving this aim, including providing increased volumes of clinical trial data supporting osteoporosis prevention, patient as well as physician education, and subsidizing either the purchase of DEXA scanning machines or the patient’s first DEXA scan. Strategic Perspectives 2001: Menopausal Disorders and Osteoporosis provides an in-depth evaluation of osteoporosis and menopausal disorders epidemiology, current market dynamics, recommended company strategies and major pipeline products and forecasts the performance of key drugs to 2008.
Get Full Details About This Report >>
|
